BioXcel Therapeutics (BTAI) Misses Q3 EPS by 45c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q3 EPS of ($1.72), $0.45 worse than the analyst estimate of ($1.27). Revenue for the quarter came in at $341 thousand versus the consensus estimate of $625.81 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• ClearSign Technologies (CLIR) Tops Q2 EPS by 8c
• Wolfspeed (WOLF) Misses Q4 EPS by 174c; Offers Guidance